☰

Marcel A. van Vugt - Publications

Affiliations: 
University of Groningen, Groningen, Netherlands 
Area:
Cell cycle, dna damage, cancer
Tree Info Grants Similar researchers PubMed Report error

25/48 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Martinikova AS, Stoyanov M, Oravetzova A, Kok YP, Yu S, Dobrovolna J, Janscak P, van Vugt M, Macurek L. PPM1D activity promotes the replication stress caused by cyclin E1 overexpression. Molecular Oncology. PMID 37067201 DOI: 10.1002/1878-0261.13433  0.344
2020 Benedict B, van Bueren MA, van Gemert FP, Lieftink C, Guerrero Llobet S, van Vugt MA, Beijersbergen RL, Te Riele H. The RECQL helicase prevents replication fork collapse during replication stress. Life Science Alliance. 3. PMID 32820027 DOI: 10.26508/lsa.202000668  0.34
2017 van Vugt MA. Shutting down the power supply for DNA repair in cancer cells. The Journal of Cell Biology. 216: 295-297. PMID 28122958 DOI: 10.1083/jcb.201701026  0.344
2017 Ruf S, Heberle AM, Langelaar-Makkinje M, Gelino S, Wilkinson D, Gerbeth C, Schwarz JJ, Holzwarth B, Warscheid B, Meisinger C, van Vugt MA, Baumeister R, Hansen M, Thedieck K. PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy. Autophagy. 0. PMID 28102733 DOI: 10.1080/15548627.2016.1263781  0.396
2016 de Boer HR, Guerrero Llobet S, van Vugt MA. Controlling the response to DNA damage by the APC/C-Cdh1. Cellular and Molecular Life Sciences : Cmls. 73: 949-60. PMID 26650195 DOI: 10.1007/s00018-015-2096-7  0.472
2015 Heijink AM, Blomen VA, Bisteau X, Degener F, Matsushita FY, Kaldis P, Foijer F, van Vugt MA. A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity. Proceedings of the National Academy of Sciences of the United States of America. 112: 15160-5. PMID 26598692 DOI: 10.1073/pnas.1505283112  0.36
2015 Hengeveld RC, de Boer HR, Schoonen PM, de Vries EG, Lens SM, van Vugt MA. Rif1 Is Required for Resolution of Ultrafine DNA Bridges in Anaphase to Ensure Genomic Stability. Developmental Cell. 34: 466-74. PMID 26256213 DOI: 10.1016/j.devcel.2015.06.014  0.391
2015 Krajewska M, Fehrmann RS, de Vries EG, van Vugt MA. Regulators of homologous recombination repair as novel targets for cancer treatment. Frontiers in Genetics. 6: 96. PMID 25852742 DOI: 10.3389/fgene.2015.00096  0.399
2014 Lafranchi L, de Boer HR, de Vries EG, Ong SE, Sartori AA, van Vugt MA. APC/C(Cdh1) controls CtIP stability during the cell cycle and in response to DNA damage. The Embo Journal. 33: 2860-79. PMID 25349192 DOI: 10.15252/embj.201489017  0.38
2010 Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MA, Wang X, Linding R, Ong SE, Weaver D, Carr SA, Yaffe MB. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Molecular Cell. 40: 34-49. PMID 20932473 DOI: 10.1016/J.Molcel.2010.09.018  0.664
2010 van Harn T, Foijer F, van Vugt M, Banerjee R, Yang F, Oostra A, Joenje H, te Riele H. Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. Genes & Development. 24: 1377-88. PMID 20551164 DOI: 10.1101/gad.580710  0.37
2010 van Vugt MA, Gardino AK, Linding R, Ostheimer GJ, Reinhardt HC, Ong SE, Tan CS, Miao H, Keezer SM, Li J, Pawson T, Lewis TA, Carr SA, Smerdon SJ, Brummelkamp TR, et al. A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint. Plos Biology. 8: e1000287. PMID 20126263 DOI: 10.1371/Journal.Pbio.1000287  0.695
2007 Linding R, Jensen LJ, Ostheimer GJ, van Vugt MA, Jørgensen C, Miron IM, Diella F, Colwill K, Taylor L, Elder K, Metalnikov P, Nguyen V, Pasculescu A, Jin J, Park JG, et al. Systematic discovery of in vivo phosphorylation networks. Cell. 129: 1415-26. PMID 17570479 DOI: 10.1016/J.Cell.2007.05.052  0.569
2007 Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB. 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 446: 329-32. PMID 17361185 DOI: 10.1038/Nature05584  0.611
2006 Freire R, van Vugt MA, Mamely I, Medema RH. Claspin: timing the cell cycle arrest when the genome is damaged. Cell Cycle (Georgetown, Tex.). 5: 2831-4. PMID 17172868 DOI: 10.4161/cc.5.24.3559  0.699
2006 Mamely I, van Vugt MA, Smits VA, Semple JI, Lemmens B, Perrakis A, Medema RH, Freire R. Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. Current Biology : Cb. 16: 1950-5. PMID 16934469 DOI: 10.1016/j.cub.2006.08.026  0.695
2006 Tanenbaum ME, Galjart N, van Vugt MA, Medema RH. CLIP-170 facilitates the formation of kinetochore-microtubule attachments. The Embo Journal. 25: 45-57. PMID 16362039 DOI: 10.1038/Sj.Emboj.7600916  0.6
2005 van Vugt MA, Bràs A, Medema RH. Restarting the cell cycle when the checkpoint comes to a halt. Cancer Research. 65: 7037-40. PMID 16103048 DOI: 10.1158/0008-5472.CAN-05-1054  0.643
2005 van Vugt MA, Medema RH. Getting in and out of mitosis with Polo-like kinase-1. Oncogene. 24: 2844-59. PMID 15838519 DOI: 10.1038/sj.onc.1208617  0.706
2005 van de Weerdt BC, van Vugt MA, Lindon C, Kauw JJ, Rozendaal MJ, Klompmaker R, Wolthuis RM, Medema RH. Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1. Molecular and Cellular Biology. 25: 2031-44. PMID 15713655 DOI: 10.1128/MCB.25.5.2031-2044.2005  0.609
2005 van Vugt MA, Medema RH. Polo-like kinase-1: activity measurement and RNAi-mediated knockdown. Methods in Molecular Biology (Clifton, N.J.). 296: 355-69. PMID 15576944  0.625
2004 van Vugt MA, Medema RH. Checkpoint adaptation and recovery: back with Polo after the break. Cell Cycle (Georgetown, Tex.). 3: 1383-6. PMID 15492511 DOI: 10.4161/cc.3.11.1248  0.688
2004 van Vugt MA, Brás A, Medema RH. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Molecular Cell. 15: 799-811. PMID 15350223 DOI: 10.1016/J.MOLCEL.2004.07.015  0.661
2004 van Vugt MA, van de Weerdt BC, Vader G, Janssen H, Calafat J, Klompmaker R, Wolthuis RM, Medema RH. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. The Journal of Biological Chemistry. 279: 36841-54. PMID 15210710 DOI: 10.1074/JBC.M313681200  0.645
2001 van Vugt MA, Smits VA, Klompmaker R, Medema RH. Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-dependent fashion. The Journal of Biological Chemistry. 276: 41656-60. PMID 11514540 DOI: 10.1074/JBC.M101831200  0.669
Low-probability matches (unlikely to be authored by this person)
2012 Roossink F, Wieringa HW, Noordhuis MG, ten Hoor KA, Kok M, Slagter-Menkema L, Hollema H, de Bock GH, Pras E, de Vries EG, de Jong S, van der Zee AG, Schuuring E, Wisman GB, van Vugt MA. The role of ATM and 53BP1 as predictive markers in cervical cancer. International Journal of Cancer. Journal International Du Cancer. 131: 2056-66. PMID 22323184 DOI: 10.1002/ijc.27488  0.3
2015 Alves IT, van Vugt MA. Plk1 Manages DNA break repair during mitosis. Cell Cycle (Georgetown, Tex.). 14: 1356-7. PMID 25789670 DOI: 10.1080/15384101.2015.1024586  0.292
2014 Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer. Gynecologic Oncology. 133: 591-8. PMID 24657486 DOI: 10.1016/j.ygyno.2014.03.557  0.289
2016 de Boer HR, Llobet SG, van Vugt MA. Erratum to: Controlling the response to DNA damage by the APC/C-Cdh1. Cellular and Molecular Life Sciences : Cmls. PMID 27251328 DOI: 10.1007/s00018-016-2279-x  0.284
2015 van Vugt MA, Reinhardt HC. Editorial: Cancer-Associated Defects in the DNA Damage Response: Drivers for Malignant Transformation and Potential Therapeutic Targets. Frontiers in Genetics. 6: 355. PMID 26734064 DOI: 10.3389/fgene.2015.00355  0.269
2017 Talens F, Jalving M, Gietema JA, Van Vugt MA. Therapeutic targeting and patient selection for cancers with homologous recombination defects. Expert Opinion On Drug Discovery. 12: 565-581. PMID 28425306 DOI: 10.1080/17460441.2017.1322061  0.259
2015 Wieringa HW, van der Zee AG, de Vries EG, van Vugt MA. Breaking the DNA damage response to improve cervical cancer treatment. Cancer Treatment Reviews. PMID 26643553 DOI: 10.1016/j.ctrv.2015.11.008  0.233
2016 Fedoseienko A, Wieringa HW, Wisman GB, Duiker E, Reyners AK, Hofker MH, van der Zee AG, van de Sluis B, van Vugt MA. Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. Plos One. 11: e0165385. PMID 27788210 DOI: 10.1371/journal.pone.0165385  0.202
2018 Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, ... ... van Vugt M, et al. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer Cell. 33: 1078-1093.e12. PMID 29894693 DOI: 10.1016/J.Ccell.2018.05.008  0.167
2016 Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 24: 55-69. PMID 26830315 DOI: 10.1016/j.drup.2015.11.005  0.159
2014 Domanska UM, Boer JC, Timmer-Bosscha H, van Vugt MA, Hoving HD, Kliphuis NM, Rosati S, van der Poel HG, de Jong IJ, de Vries EG, Walenkamp AM. CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model. Clinical & Experimental Metastasis. 31: 829-39. PMID 25154297 DOI: 10.1007/s10585-014-9673-2  0.154
2013 Huisman C, Wisman GB, Kazemier HG, van Vugt MA, van der Zee AG, Schuuring E, Rots MG. Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors. Molecular Oncology. 7: 669-79. PMID 23522960 DOI: 10.1016/j.molonc.2013.02.017  0.147
2013 Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S. Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer. Expert Reviews in Molecular Medicine. 15: e12. PMID 24074238 DOI: 10.1017/erm.2013.13  0.127
2019 Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Llobet SG, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, ... ... van Vugt M, et al. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. Cancer Cell. 35: 950-952. PMID 31185216 DOI: 10.1016/j.ccell.2019.05.012  0.12
2013 Bensch F, van Kruchten M, Lamberts LE, Schröder CP, Hospers GA, Brouwers AH, van Vugt MA, de Vries EG. Molecular imaging for monitoring treatment response in breast cancer patients. European Journal of Pharmacology. 717: 2-11. PMID 23545359 DOI: 10.1016/j.ejphar.2013.01.079  0.12
2015 Fehrmann RS, Karjalainen JM, Krajewska M, Westra HJ, Maloney D, Simeonov A, Pers TH, Hirschhorn JN, Jansen RC, Schultes EA, van Haagen HH, de Vries EG, te Meerman GJ, Wijmenga C, van Vugt MA, et al. Gene expression analysis identifies global gene dosage sensitivity in cancer. Nature Genetics. 47: 115-25. PMID 25581432 DOI: 10.1038/Ng.3173  0.115
2017 Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JB, van Vugt MA, de Vries EG, Schröder CP, Fehrmann RS. Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. Journal of the National Cancer Institute. 109. PMID 27737921 DOI: 10.1093/jnci/djw192  0.109
2018 de Jong MRW, Visser L, Huls G, Diepstra A, van Vugt M, Ammatuna E, van Rijn RS, Vellenga E, van den Berg A, Fehrmann RSN, van Meerten T. Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. Plos One. 13: e0193098. PMID 29489886 DOI: 10.1371/journal.pone.0193098  0.105
2011 Heijink DM, de Vries EG, Koornstra JJ, Hospers GA, Hofstra RM, van Vugt MA, de Jong S, Kleibeuker JH. Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. Critical Reviews in Oncology/Hematology. 80: 264-77. PMID 21159521 DOI: 10.1016/j.critrevonc.2010.11.009  0.09
2015 Tamas K, Domanska UM, van Dijk TH, Timmer-Bosscha H, Havenga K, Karrenbeld A, Sluiter WJ, Beukema JC, van Vugt MA, de Vries EG, Hospers GA, Walenkamp AM. CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. Current Pharmaceutical Design. 21: 2276-83. PMID 25557636 DOI: 10.2174/1381612821666150105155615  0.078
2011 de Vries EG, Oude Munnink TH, van Vugt MA, Nagengast WB. Toward molecular imaging-driven drug development in oncology. Cancer Discovery. 1: 25-8. PMID 22586317 DOI: 10.1158/2159-8274.CD-11-0051  0.075
2015 Tamas K, Walenkamp AM, de Vries EG, van Vugt MA, Beets-Tan RG, van Etten B, de Groot DJ, Hospers GA. Rectal and colon cancer: Not just a different anatomic site. Cancer Treatment Reviews. 41: 671-9. PMID 26145760 DOI: 10.1016/j.ctrv.2015.06.007  0.071
1987 Tonnaer JA, van Vugt MA, de Boer T, de Graaf JS. Differential interactions of muscarinic drugs with binding sites of [3H]pirenzepine and [3H]quinuclidinyl benzilate in rat brain tissue. Life Sciences. 40: 1981-7. PMID 3573989 DOI: 10.1016/0024-3205(87)90287-6  0.021
Hide low-probability matches.